title: Treatment with recombinant human erythropoietin in patients with aluminum overload and hyperparathyroidism.
abstract: In a European multicenter trial the weekly rates of increase in hematocrit and reticulocyte values were investigated in hemodialyzed patients with transfusion-dependent anemia treated with recombinant human erythropoietin (rHuEPO). Within a few months of therapy, the number of transfusion-dependent patients decreased to less than 5% of the group. Patients with aluminum overload indicated by elevated basal serum levels or elevated levels after a desferrioxamine challenge showed a significantly reduced response to rHuEPO. whereas in patients with elevated levels of parathyroid hormone a normal response to rHuEPO was found.
authors.affiliation: II Medical Clinic, St. Markus Hospital, Frankfurt, FRG.
authors.forename: P
authors.initials: P
authors.lastname: Grützmacher
authors.forename: B
authors.initials: B
authors.lastname: Ehmer
authors.forename: J
authors.initials: J
authors.lastname: Limbach
authors.forename: D
authors.initials: D
authors.lastname: Messinger
authors.forename: K D
authors.initials: KD
authors.lastname: Kulbe
authors.forename: P
authors.initials: P
authors.lastname: Scigalla
mesh_terms: D000535:Aluminum / Q000097:blood*; D000740:Anemia / Q000188:drug therapy* / Q000209:etiology; D001853:Bone Marrow / Q000187:drug effects; D004921:Erythropoietin / Q000627:therapeutic use*; D005060:Europe; D006403:Hematologic Tests; D006801:Humans; D006961:Hyperparathyroidism / Q000150:complications*; D011994:Recombinant Proteins / Q000627:therapeutic use; D006435:Renal Dialysis / Q000009:adverse effects*
chemical_list: D011994:Recombinant Proteins; D004921:Erythropoietin; D000535:Aluminum